Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial
Management of Diabetic Peripheral Neuropathy Andrew J.M. Boulton , MD, DSc(Hon), FRCP Abstract IN BRIEF Diabetic peripheral neuropathy affects up to 50% of older type 2 diabetic patients. Whereas some patients may have extremely painful symptoms, others with a more marked neuropathic deficit may be...
Gespeichert in:
Veröffentlicht in: | Diabetes care 2000-01, Vol.23 (1), p.9 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Management of Diabetic Peripheral Neuropathy
Andrew J.M. Boulton , MD, DSc(Hon), FRCP
Abstract
IN BRIEF
Diabetic peripheral neuropathy affects up to 50% of older type 2 diabetic
patients. Whereas some patients may have extremely painful symptoms, others
with a more marked neuropathic deficit may be asymptomatic. Diagnosis requires
careful examination of the lower limbs. Management involves establishing that
the neuropathy is caused by diabetes instead of more sinister causes and
aiming for optimal glycemic control. Medications, usually tricyclic drugs or
anticonvulsant agents, may be required. Patients with peripheral neuropathy
must be considered at risk of insensate foot ulceration and must receive
preventive education and podiatric care.
Footnotes
Andrew J.M. Boulton, MD, DSc(Hon), FRCP, is a professor of medicine at
the University of Manchester, U.K., and the University of Miami in Miami,
Fla.
Note of disclosure: Dr. Boulton has received honoraria for
speaking engagements or consulting fees from Pfizer and Eli Lilly. These
companies manufacture drugs for treatment of neuropathic pain.
American Diabetes Association |
---|---|
ISSN: | 0149-5992 0891-8929 1945-4953 1935-5548 |
DOI: | 10.2337/diaclin.23.1.9 |